Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. (22nd March 2011)

• Record Type: Journal Article
• Authors: Marshall, Gayle; Howard, Zoe; Dry, Jonathan; Fenton, Sarah; Heathcote, Dan; Gray, Neil; Keen, Heather; Logie, Armelle; Holt, Sarah; Smith, Paul; Guichard, Sylvie M.
• Is Part Of: Biochemical Society transactions. Volume 39:Number 2(2011)
• Page Start: 456
• Page End: 459
• Publication Date: 2011-03-22
• Subjects: Akt -- AZD8055 -- mammalian target of rapamycin complex (mTORC) -- mammalian target of rapamycin kinase (mTOR kinase) -- oncology; Biochemistry -- Congresses; 572
• DOI: 10.1042/BST0390456
• Languages: English
• ISSNs: 0300-5127

Abstract

Abstract : AZD8055 is a small-molecule inhibitor of mTOR (mammalian target of rapamycin) kinase activity. The present review highlights molecular and phenotypic differences between AZD8055 and allosteric inhibitors of mTOR such as rapamycin. Biomarkers, some of which are applicable to clinical studies, as well as biological effects such as autophagy, growth inhibition and cell death are compared between AZD8055 and rapamycin. Potential ways to develop rational combinations with mTOR kinase inhibitors are also discussed. Overall, AZD8055 may provide a better therapeutic strategy than rapamycin and analogues.